Category Archives: Global News Feed

The collaboration between SciSparc and Clearmind continues to yield positive results in its obesity and metabolic disorder program

Read this article:
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial

TORONTO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that Blair McInnis has provided notice of his resignation as Chief Financial Officer of the Company, which is effective immediately, to pursue a new opportunity. Mr. McInnis will assist the Company to ensure a smooth transition.

Originally posted here:
Spectral Medical Announces CFO Departure

The collaboration between Clearmind and SciSparc continues to yield positive results in its obesity and Metabolic disorder program

Continued here:
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in one upcoming investor conference in December.

Read the original post:
Allogene Therapeutics Announces Participation in December Investor Conference

PALO ALTO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced monthly revenue in November 2023 and provided certain preliminary unaudited financial results for gross and net sales for the one month ended November 2023 and year-to-date through November 30, 2023.

Go here to read the rest:
Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales...

MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AES) 2023 Annual Meeting in Orlando, FL on December 2, 2023.

Read the original here:
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting